NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its third quarter revenues for fiscal year 2015 dipped 2 percent.
For the second quarter in a row, the company also lowered its guidance for the fiscal year.
Total revenues for the three months ended March 31 were $180.0 million compared to $182.9 million in the third quarter of fiscal year 2014. The revenues were below the consensus Wall Street estimate of $183.3 million. Myriad attributed the decrease to severe weather conditions in the northeast during January and February.